Moreover, it was proven that an SREBF1 inhibitor could significantly reduce BMSC‐derived adipogenesis and the subsequent contributions to sheltering T‐ALL cells; so inhibiting SREBF1 may be a feasible strategy to solve the dilemma of recurrence in T‐ALL. The gene discussed is SREBF1; the disease is acute lymphoblastic leukemia.